Either way, there is absolutely zero solid evidence communicated by Resverlogix official communications that reaching 3300 patient years makes any difference. The trial was originally designed to accrue approximately 3600 patient years. 3300? 3600? It doesn't matter, IMO. Hitting 250 events is and has always been the stated trial end trigger. Personally, I put more weight on the statements/guidance made at the more recent AGM that I pointed out in my previous message.

BearDownAZ